newsfilter
← Latest News
GlobeNewswire·

Eikon Therapeutics Submits IND for Novel Androgen Receptor Antagonist EIK1006 in Prostate Cancer

  • Eikon Therapeutics submitted an Investigational New Drug (IND) application to the U.S. FDA on October 15, 2026, for EIK1006 to treat advanced metastatic prostate cancer.
  • EIK1006 is a novel androgen receptor antagonist structurally unrelated to existing lutamide-class antagonists.
  • The company utilized its proprietary single molecule tracking system to optimize EIK1006 for potency against wild-type and clinically relevant androgen receptor variants.
  • Eikon aims to advance its oncology pipeline by integrating traditional biology research with advanced engineering to address unmet medical needs.
  • Forward-looking statements regarding clinical trial initiation, FDA review timelines, and potential data readouts are included but subject to significant risks including financial losses, funding needs, and regulatory uncertainties.